Dyne Therapeutics (DYN) AI Stock Analysis

• Market Cap: $2.41B
• Dividend Yield: N/A
• Average Volume (3M): 1.80M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.87
• Revenue Growth: N/A
• EPS Growth: -2.75%
• Country: US
• Employees: 192
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.76
• Shares Outstanding: 165,027,110
• 10 Day Avg. Volume: 1,767,971
• 30 Day Avg. Volume: 1,796,420
• PEG Ratio: -1.90
• Price to Book (P/B): 2.58
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.20
• Enterprise Value/Market Cap: 0.68
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -3.77
• 1Y Price Target: $38.25
• Price Target Upside: 161.99% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8
• EPS Forecast (FY): -3.25
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: $16.50 ▲(13.01% Upside)
• Action: Reiterated Date: 03/03/26
• Date: Action: Reiterated 03/03/26

Overall score is held back primarily by weak financial performance (no revenue, widening losses, and accelerating cash burn). Technicals also lean negative in the near term. Offsetting these, recent corporate events were constructive, highlighting positive clinical progress and an extended cash runway, while valuation support is limited due to negative earnings and no dividend.

Positive Factors

FORCE platform clinical validation

The DELIVER registrational expansion met its primary endpoint with increased dystrophin expression, providing clinical validation of Dyne’s FORCE delivery technology. This durable evidence supports platform credibility across programs and strengthens the company’s ability to advance multiple candidates toward registration and commercialization.

Near-term regulatory/commercial path

A defined path to seek U.S. Accelerated Approval and a potential commercial launch within a ~12-month window materially shortens the timeline to revenue generation for z-rostudirsen. This near-term regulatory plan concentrates development resources but, if realized, converts clinical progress into sustainable commercial operations and partnerships.

Extended cash runway and low leverage

An ending cash position of roughly $1.1B, supplemented by an upsized $350M offering, provides a multi-year runway into early 2028 and lowers immediate financing pressure. Combined with very low debt-to-equity, this financial flexibility supports continued R&D, registrational trials, and initial commercial investments through key regulatory milestones.

Negative Factors

Pre-revenue company

Dyne remains entirely pre-revenue across multiple years, meaning long-term value depends on successful clinical development and commercialization of first products. The absence of product sales leaves the business reliant on milestones and external funding rather than operating cash flow, elevating execution and funding risk over the medium term.

Widening losses and accelerating cash burn

Losses and cash burn have widened materially, with 2025 operating and free cash flows deeply negative. Sustained heavy R&D and clinical costs increase the need for capital raises and create dilution risk. If execution timelines slip or trials expand, burn could accelerate further, pressuring the durability of the current runway.

High dependence on positive regulatory outcomes

The company’s path to commercialization is highly binary, hinging on regulatory approval for lead programs. While a validated platform reduces technical risk, business success depends on favorable FDA decisions and subsequent uptake. Regulatory setbacks would materially delay revenue and likely require additional financing rounds.

Dyne Therapeutics Business Overview & Revenue Model

Company Description

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..

How the Company Makes Money

Dyne Therapeutics generates revenue primarily through strategic collaborations, partnerships, and licensing agreements with other biotechnology and pharmaceutical companies. These partnerships often involve upfront payments, milestone payments for achieving specific clinical or regulatory goals, and royalties on sales of any successfully commercialized products. Additionally, Dyne may receive funding through research grants and government contracts aimed at advancing its therapeutic programs. As the company progresses towards commercialization, potential revenue streams could also include direct sales of approved therapies or sublicensing opportunities with other entities.

Dyne Therapeutics Financial Statement Overview

Summary

Well-capitalized and low leverage (debt-to-equity ~0.02) supports near-term R&D execution, but the company is pre-revenue with sharply widening losses (net loss ~-$446M in 2025) and accelerating cash burn (operating cash flow ~-$403M; free cash flow ~-$405M in 2025), increasing ongoing financing dependence.

Income Statement

Dyne Therapeutics remains pre-revenue (revenue is $0 across 2020–2025), with losses widening materially over time. Net loss increased from about $59M (2020) to about $446M (2025), and EBIT/EBITDA losses similarly expanded (EBIT about -$468M in 2025). The key strength is that the company is investing heavily toward future commercialization, but the main weakness is the lack of revenue base and consistently deepening profitability profile.

Balance Sheet

The balance sheet is a relative bright spot: leverage is low, with debt-to-equity improving to ~0.02 in 2025 (total debt ~$20M against equity ~$972M). Total assets rose substantially to ~$1.19B in 2025, reflecting a strong funding position for a development-stage biotech. The weakness is persistent negative returns on equity (about -46% in 2025) driven by large losses, which can pressure capital over time if burn remains elevated.

Cash Flow

Cash generation is weak, with operating cash flow and free cash flow consistently negative and the cash burn accelerating (operating cash flow from about -$47M in 2020 to about -$403M in 2025; free cash flow about -$405M in 2025). A positive is that free cash flow generally tracks net income closely (free cash flow to net income ~1.0 in recent years), suggesting losses are largely reflected in cash usage rather than hidden working-capital effects. The key risk is the scale and upward trend of cash burn, which increases dependence on external financing.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-2.05M	-2.24M	-2.46M	0.00	0.00
EBITDA	-437.97M	-315.18M	-233.48M	-169.28M	-148.94M
Net Income	-446.21M	-317.42M	-235.94M	-168.10M	-149.29M
Balance Sheet
Total Assets	1.19B	691.23M	165.08M	306.32M	425.66M
Cash, Cash Equivalents and Short-Term Investments	1.11B	642.27M	123.10M	256.01M	376.57M
Total Debt	20.28M	23.99M	27.41M	30.48M	32.64M
Total Liabilities	214.83M	61.40M	73.79M	53.96M	57.47M
Stockholders Equity	972.13M	629.84M	91.29M	252.36M	368.20M
Cash Flow
Free Cash Flow	-405.13M	-294.75M	-188.89M	-156.71M	-123.18M
Operating Cash Flow	-403.21M	-292.37M	-188.16M	-153.65M	-119.56M
Investing Cash Flow	-28.75M	-204.08M	83.31M	87.20M	-137.89M
Financing Cash Flow	890.31M	809.89M	54.32M	37.39M	157.82M

Dyne Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 14.60
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DYN, the sentiment is Negative. The current price of 14.6 is below the 20-day moving average (MA) of 15.98, below the 50-day MA of 17.44, and below the 200-day MA of 15.10, indicating a neutral trend. The MACD of -0.62 indicates Negative momentum. The RSI at 41.64 is Neutral, neither overbought nor oversold. The STOCH value of 56.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DYN.

Dyne Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ARQT	63 Neutral	$2.99B	-228.91	-9.30%	―	129.21%	80.35%
BEAM	63 Neutral	$2.77B	-34.27	-8.11%	―	-84.07%	-157.71%
IMCR	53 Neutral	$1.64B	―	-9.59%	―	27.51%	38.72%
DYN	52 Neutral	$2.41B	-5.63	-55.71%	―	―	-2.75%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
COGT	49 Neutral	$6.01B	-7.30	-73.70%	―	―	4.32%
SRPT	48 Neutral	$1.67B	-3.16	-63.17%	―	47.15%	-311.26%

Dyne Therapeutics Corporate Events

Dyne Therapeutics Highlights Pipeline and Cash at JPM Conference

On January 12, 2026, Dyne Therapeutics released an investor presentation at the J.P. Morgan Healthcare Conference outlining its current operations, late-stage clinical pipeline and plans to advance its FORCE platform-based neuromuscular therapies toward commercialization. The company highlighted positive topline data from a registrational cohort of its Duchenne muscular dystrophy candidate zeleciment rostudirsen, ongoing registrational work in myotonic dystrophy type 1, and a strong cash position of roughly $1.1 billion as of December 31, 2025, supporting operations into the first quarter of 2028 and enabling a steady schedule of data readouts and regulatory submissions ahead of a targeted first commercial launch in early 2027; together with emerging clinical validation of its targeted delivery technology, these developments position Dyne as a potential best-in-class player in rare neuromuscular disease and signal material implications for future revenue generation and competitive standing in the sector.

The most recent analyst rating on (DYN) stock is a Hold with a $20.00 price target. To see the full list of analyst forecasts on Dyne Therapeutics stock, see the DYN Stock Forecast page.

Dyne Therapeutics Appoints Vikram Karnani to Board

On December 22, 2025, Dyne Therapeutics, Inc.’s board of directors elected Vikram Karnani as an independent Class II director, with a term running until the company’s 2028 annual meeting of stockholders, signaling continued attention to board independence and governance. Karnani will receive standard non-employee director compensation, including an option to purchase 59,665 shares at $20.78 per share vesting over three years, annual cash and equity compensation, and reimbursement of board-related expenses, with no related-party relationships or transactions disclosed and with his role governed by the company’s standard indemnification agreement.

The most recent analyst rating on (DYN) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on Dyne Therapeutics stock, see the DYN Stock Forecast page.

Dyne Therapeutics Announces Upsized Public Offering

On December 9, 2025, Dyne Therapeutics announced the pricing of an upsized underwritten public offering of 18,980,478 shares of its common stock at $18.44 per share, expected to raise $350 million before expenses. The offering, managed by Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities, is anticipated to close around December 11, 2025, with an option for underwriters to purchase additional shares. The proceeds, combined with existing resources, are expected to fund Dyne’s operations into the first quarter of 2028, enhancing its financial runway and supporting its strategic initiatives in the neuromuscular disease sector.

The most recent analyst rating on (DYN) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Dyne Therapeutics stock, see the DYN Stock Forecast page.

Dyne Therapeutics Amends Loan Agreement for $50 Million

On December 8, 2025, Dyne Therapeutics, Inc. amended its Loan and Security Agreement with Hercules Capital, Inc. and other lenders, allowing the company to borrow a second term loan tranche of $50 million. This amendment provides Dyne Therapeutics with additional financial flexibility, enabling access to further tranches totaling up to $125 million, contingent on achieving certain milestones, and extends the interest-only payment period under specific conditions.

The most recent analyst rating on (DYN) stock is a Buy with a $44.00 price target. To see the full list of analyst forecasts on Dyne Therapeutics stock, see the DYN Stock Forecast page.

Dyne Therapeutics Reports Positive Phase 1/2 Trial Results

On December 8, 2025, Dyne Therapeutics announced positive topline results from its Phase 1/2 DELIVER trial for zeleciment rostudirsen (z-rostudirsen) in individuals with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping. The trial’s Registrational Expansion Cohort (REC) met its primary endpoint, showing a statistically significant increase in muscle content-adjusted dystrophin expression. Additionally, long-term data from the ongoing open-label and long-term extension portions of the trial demonstrated sustained functional improvement and a favorable safety profile. These results position Dyne Therapeutics to submit for U.S. Accelerated Approval in the second quarter of 2026, with a potential U.S. launch in the first quarter of 2027, assuming FDA approval.

The most recent analyst rating on (DYN) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on Dyne Therapeutics stock, see the DYN Stock Forecast page.